Rafferty Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-3,424
| Closed | -$349K | – | 1112 |
|
|
2023
Q2 | $349K | Buy |
+3,424
| New | +$349K | ﹤0.01% | 1028 |
|
|
2022
Q1 | – | Sell |
-11,450
| Closed | -$302K | – | 1344 |
|
|
2021
Q4 | $302K | Buy |
11,450
+4,633
| +68% | +$122K | ﹤0.01% | 1151 |
|
|
2021
Q3 | $686K | Buy |
6,817
+4,215
| +162% | +$424K | ﹤0.01% | 970 |
|
|
2021
Q2 | $368K | Buy |
2,602
+94
| +4% | +$13.3K | ﹤0.01% | 1133 |
|
|
2021
Q1 | $250K | Sell |
2,508
-882
| -26% | -$87.9K | ﹤0.01% | 1114 |
|
|
2020
Q4 | $419K | Sell |
3,390
-352
| -9% | -$43.5K | ﹤0.01% | 722 |
|
|
2020
Q3 | $365K | Buy |
3,742
+1,911
| +104% | +$186K | ﹤0.01% | 762 |
|
|
2020
Q2 | $286K | Buy |
+1,831
| New | +$286K | ﹤0.01% | 841 |
|
|
2020
Q1 | – | Sell |
-1,970
| Closed | -$403K | – | 845 |
|
|
2019
Q4 | $403K | Sell |
1,970
-1,272
| -39% | -$260K | 0.01% | 725 |
|
|
2019
Q3 | $260K | Buy |
+3,242
| New | +$260K | ﹤0.01% | 760 |
|